Big Pharma is just getting started

The Great Reset has its many beneficiaries. Twenty-two years ago, on LewRockwell.com, I started pointing out where the vaccine propaganda campaign was headed. I was considered a “loon.”

“The numbers are unprecedented,” Rasmus Beck Hansen, CEO of Airfinity, told the Financial Times.

More fear campaigns = more revenue streams.

After a breakout year, Moderna sees strong reason to believe 2021 won’t be a one-off boom year. That’s thanks to the predicted need for booster shots and additional supply deals coupled with stronger pricing power, Jefferies analysts wrote to clients Thursday following a conversation with CEO Stéphane Bancel.

The Jefferies team thinks Moderna could drive $15 billion in 2022 revenues, with an upper limit of $30 billion. Where the company lands will depend on how the pandemic progresses, fear of infection and whether the company can produce future products, like a combo shot against COVID and the flu.

 

Share

7:24 am on October 27, 2021